Your browser doesn't support javascript.
loading
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman, Geoffrey J; Fernando, Tharu M; Bowen, Rebecca; Jerzak, Katarzyna J; Song, Xinni; Decker, Thomas; Boyle, Frances; McCune, Steve; Armstrong, Anne; Shannon, Catherine; Bertelli, Gianfilippo; Chang, Ching-Wei; Desai, Rupal; Gupta, Kushagra; Wilson, Timothy R; Flechais, Aulde; Bardia, Aditya.
Afiliação
  • Lindeman GJ; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Fernando TM; Cancer Biology and Stem Cells Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
  • Bowen R; Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia.
  • Jerzak KJ; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Song X; Medical Oncology, Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom.
  • Decker T; Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada.
  • Boyle F; Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada.
  • McCune S; Hematology and Oncology, Onkologie Ravensburg, Ravensburg, Germany.
  • Armstrong A; Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney, Australia.
  • Shannon C; Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Bertelli G; Medical Oncology, Wellstar Health System, Marietta, Georgia.
  • Chang CW; Medical Oncology, The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom.
  • Desai R; Medical Oncology, Mater Cancer Care Centre, Brisbane, Australia.
  • Gupta K; Medical Oncology, Royal Sussex County Hospital, Brighton, United Kingdom.
  • Wilson TR; PHC and Early Development Oncology Biostatistics, Genentech, Inc., South San Francisco, California.
  • Flechais A; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Bardia A; Biostatistics, IQVIA RDS (India) Private Ltd, Bangalore, India.
Clin Cancer Res ; 28(15): 3256-3267, 2022 08 02.
Article em En | MEDLINE | ID: mdl-35583555
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article